In most European countries, absences from work and early retirement due to mental illness have increased in recent years. Mental health conditions such as depression, anxiety and stress represent substantial financial costs for employers and employees, as well as a significant loss for society at large. An EU-level estimate of the overall costs, direct health costs and lost productivity is more than 450 billion EUR per year.
Each year, an estimated 213 million women become pregnant and 140 million newborn babies are delivered. However, many of the women and infants receive no appropriate care or care that is below evidence-based standards; others suffer from over-medicalisation. Access to quality care, during and after pregnancy, is essential to ensure good maternal health and the favourable early development of the child.
Citizens in a rapidly ageing European population are at greater risk of cognitive impairment, frailty and multiple chronic health conditions with considerable negative consequences for their independence, quality of life and for the sustainability of health and care systems. The challenge is to foster large-scale deployment of integrated digital solutions which will bring improved quality of life to citizens while demonstrating significant efficiency gains in health and care delivery across Europe.
Despite the general acknowledgement by the scientific community that 'Genetics load the gun but environment pulls the trigger' when it comes to the causation of major non-communicable diseases (NCDs), there is persistent uncertainty as to the global burden of disease attributable to environmental (including life-style and climatic) factors, including healthcare costs and negative economic impact. Deciphering the human exposome is a novel way of addressing the challenge to improve health and reduce the overall burden of disease.
Personalised medicine (PM) has the potential to respond to, among others, the increasing burden of co-morbidities and thus enhance the sustainability of healthcare systems. With the increasing number of scientific approaches available, it is crucial to demonstrate the benefit of large scale deployment of personalised medicine to citizens and healthcare systems. This was also one of the conclusions of the Personalised Medicine Conference 2016.
The increasing number of individuals with co-and multimorbidities poses an urgent need to improve management of patients with multiple co-existing diseases. A better understanding of their causative mechanisms is needed to develop early diagnosis, efficient prevention and monitoring, and better treatments adapted to co- and multimorbid patients throughout their life course. Furthermore, there are many different etiological models of comorbid conditions (e.g., direct causation model or a consequence of treatment).
This call for funding is part of a broader international funding framework entitled "Global Issues – Integrating Different Perspectives”, which aims to enable international research collaboration and to generate new insights on understudied issues of global relevance. The different thematic areas that are addressed through this overarching funding scheme are oriented towards those challenges that have been acknowledged by the United Nations’ sustainable development agenda as requiring specific action.
Rila est le Partenariat Hubert Curien (PHC) franco-bulgare. Il est mis en œuvre en Bulgarie par Fonds national pour la science, du Ministère de l'Éducation et de la Science, et en France par le ministère de l'Europe et des Affaires étrangères (MEAE) et le ministère chargé de l'Enseignement supérieur et de la Recherche (MESR).
Les appels à candidatures de ce programme sont lancés sur un rythme annuel.
Date limite de dépôt des dossiers de candidature : 2 juillet 2025
